Company Description
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases.
The company’s lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer’s disease.
It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019.
Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
| Country | United States |
| Founded | 1990 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 8 |
| CEO | N. Fine |
Contact Details
Address: 6714 NW 16th Street, Suite B Gainesville, Florida 32653 United States | |
| Phone | 386 418 8060 |
| Website | cyclotherapeutics.com |
Stock Details
| Ticker Symbol | CYTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000922247 |
| CUSIP Number | 550241103 |
| ISIN Number | US23254X2018 |
| Employer ID | 59-3029743 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| N. Scott Fine | Chief Executive Officer and Director |
| C. E Strattan | Founder and Director |
| Joshua M. Fine | Chief Financial Officer and Secretary |
| Michael Eric Lisjak | Senior Vice President of Business Development and Chief Regulatory Officer |
| Dr. Jeffrey L. Tate Ph.D. | Chief Operating Officer, Chief Quality Officer and Director |
| Lori McKenna | Global Head of Patient Advocacy |
| Dr. Karen Mullen FFPM | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | 8-K | Current Report |
| Oct 9, 2024 | 8-K | Current Report |
| Oct 8, 2024 | 8-K | Current Report |
| Sep 9, 2024 | 8-K | Current Report |
| Aug 22, 2024 | 425 | Filing |
| Aug 22, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Jul 17, 2024 | 8-K | Current Report |
| Jun 28, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |